Dubai Telegraph - Mice trial raises hopes for 'on demand' male contraceptive

EUR -
AED 3.896782
AFN 71.970942
ALL 98.005181
AMD 410.245014
ANG 1.910392
AOA 969.150107
ARS 1058.535585
AUD 1.625105
AWG 1.911243
AZN 1.804916
BAM 1.952226
BBD 2.140282
BDT 126.668083
BGN 1.954125
BHD 0.39988
BIF 3130.34894
BMD 1.060918
BND 1.418709
BOB 7.350404
BRL 6.098794
BSD 1.060009
BTN 89.509273
BWP 14.421276
BYN 3.468912
BYR 20793.984215
BZD 2.136589
CAD 1.480871
CDF 3043.772641
CHF 0.937002
CLF 0.037907
CLP 1045.969635
CNY 7.661842
COP 4706.760764
CRC 542.432423
CUC 1.060918
CUP 28.114315
CVE 110.062449
CZK 25.385671
DJF 188.763289
DKK 7.459582
DOP 63.876059
DZD 141.570939
EGP 52.207642
ETB 131.000325
FJD 2.400856
GBP 0.832847
GEL 2.906642
GHS 17.277204
GMD 75.853327
GNF 9135.746941
GTQ 8.190926
GYD 221.749817
HKD 8.252734
HNL 26.751282
HTG 139.425239
HUF 411.004238
IDR 16737.512871
ILS 3.989583
INR 89.539798
IQD 1388.583814
IRR 44669.934186
ISK 147.520817
JMD 168.439542
JOD 0.752299
JPY 164.527633
KES 137.06364
KGS 91.448653
KHR 4295.439124
KMF 488.419938
KRW 1493.349953
KWD 0.326234
KYD 0.883299
KZT 526.01683
LAK 23242.540542
LBP 94922.679318
LKR 309.967089
LRD 199.802298
LSL 19.152137
LTL 3.132613
LVL 0.641738
LYD 5.135839
MAD 10.515649
MDL 18.974154
MGA 4955.161109
MKD 61.501816
MMK 3445.818857
MOP 8.49301
MRU 42.123861
MUR 50.064526
MVR 16.402021
MWK 1837.721918
MXN 21.861851
MYR 4.72746
MZN 67.819132
NAD 19.151596
NGN 1778.681478
NIO 39.010598
NOK 11.769899
NPR 143.222523
NZD 1.790898
OMR 0.408483
PAB 1.059939
PEN 4.005911
PGK 4.258364
PHP 62.296049
PKR 294.599601
PLN 4.351472
PYG 8282.226373
QAR 3.864488
RON 4.975918
RSD 116.986352
RUB 103.700317
RWF 1454.705134
SAR 3.986063
SBD 8.859994
SCR 14.916358
SDG 638.142533
SEK 11.580918
SGD 1.420892
SLE 24.18896
SOS 605.819355
SRD 37.381452
STD 21958.851549
SVC 9.275193
SZL 19.142853
THB 36.855747
TJS 11.267165
TMT 3.713211
TND 3.332367
TOP 2.48477
TRY 36.47689
TTD 7.203151
TWD 34.468683
TZS 2825.997726
UAH 43.903187
UGX 3894.795581
USD 1.060918
UYU 44.68818
UZS 13571.98253
VES 47.606636
VND 26894.260197
XAF 654.789004
XCD 2.867183
XDR 0.798576
XOF 654.789004
XPF 119.331742
YER 264.990671
ZAR 19.19911
ZMK 9549.525686
ZMW 28.858523
ZWL 341.615022
  • CMSC

    -0.1800

    24.54

    -0.73%

  • RYCEF

    -0.0500

    7.11

    -0.7%

  • BCC

    -2.0100

    141.13

    -1.42%

  • SCS

    0.0200

    13.67

    +0.15%

  • RBGPF

    59.3400

    59.34

    +100%

  • RIO

    -1.4000

    61.2

    -2.29%

  • NGG

    -1.2400

    62.9

    -1.97%

  • JRI

    -0.3000

    13.22

    -2.27%

  • BTI

    0.0900

    35.24

    +0.26%

  • GSK

    -0.8300

    35.52

    -2.34%

  • VOD

    -0.8500

    8.47

    -10.04%

  • RELX

    -1.2100

    46.59

    -2.6%

  • BCE

    -0.1600

    27.69

    -0.58%

  • CMSD

    -0.2100

    24.75

    -0.85%

  • BP

    -0.7600

    28.16

    -2.7%

  • AZN

    0.4000

    65.19

    +0.61%

Mice trial raises hopes for 'on demand' male contraceptive
Mice trial raises hopes for 'on demand' male contraceptive / Photo: PETER PARKS - AFP/File

Mice trial raises hopes for 'on demand' male contraceptive

If women have the "morning after" pill, could men one day have an "hour before" pill?

Text size:

A new drug candidate renders male mice infertile within an hour and wears off in less than a day, an experimental study said Tuesday, potentially pointing towards a future "on-demand" male contraceptive.

The potential drug, which has not been tested in humans and remains years away from possibly becoming available, joins a growing number of male contraceptives in development.

However there are currently only two options available for men: condoms and vasectomies.

Previous drugs have struggled partly because the bar for side effects is believed to be far higher for men -- because they do not risk getting pregnant -- as well as a lack of interest from the pharmaceutical industry.

"For women, right now all the burden of contraception is on us," Melanie Balbach, a pharmacology researcher at Weill Cornell Medicine in the US, told AFP.

"We want new options," said Balbach, the lead author of the study published in Nature Communications.

The team of researchers targeted an enzyme called soluble adenylyl cyclase, which acts as the "on switch" for sperm, said study co-author Jochen Buck, also of Weill Cornell Medicine.

If the enzyme is switched off, the sperm can no longer move, he said.

Across several different tests, the researchers showed that a compound which blocks the enzyme renders mice sperm immobile in 30 minutes to an hour.

The compound was 100 percent effective in preventing pregnancy within the first two hours, dropping to 91 percent in the first three hours, the study said.

After 24 hours, the mice sperm moved like normal again.

- 'Eye-catching advantage' -

The researchers hope are aiming for a single non-hormonal pill that works in under an hour and lasts six to 12 hours, Buck said.

This would be much different to other options under development, such as a hormonal gel currently going through human trials, which all take weeks or months to start and stop working.

No side effects were noticed in the mice. Previous research has suggested that infertile men who had their soluble adenylyl cyclase enzyme permanently switched off had an increased rate of kidney stones.

Buck said this was the result of their enzyme always being off -- which would not be the case for men taking an on demand pill.

The researchers hope to hold the first trials on humans within three years, with a final product possibly up to eight years away, Buck said.

Susan Walker, an expert in contraception at the UK's Anglia Ruskin University not involved in the research, said she was a "little sceptical" a pill would actually make it to market as so many other efforts have fallen short.

But the "eye-catching advantage" of almost immediate effectiveness offered "the possibility of seeing a sexual partner take a pill," she said.

The consultancy Desire Line is working on forecasting the potential uptake of a range of male contraceptive products, according to its founder Steve Kretschmer.

"Initial estimates indicate in the United States that uptake for an on-demand pill which has quick onset of action and 1-2 days duration of action could be about triple that of Viagra when it was initially launched," he told AFP.

B.Krishnan--DT